Prostaglandins and extracorporeal circulation.

[1]  G. Tuszynski,et al.  Temporary inhibition of platelet function with iloprost (ZK36374) preserves canine platelets during extracorporeal membrane oxygenation. , 1988, The Journal of thoracic and cardiovascular surgery.

[2]  J. Bhayana,et al.  Beneficial effects of prostaglandin E1 on autoperfused heart-lung preservation. , 1988, The Journal of heart transplantation.

[3]  T. English,et al.  Selection and procurement of combined heart and lung grafts for transplantation. , 1988, The Journal of thoracic and cardiovascular surgery.

[4]  A. Vezzani,et al.  [Blood saving in heart surgery. Personal experience with 232 patients]. , 1988, Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma.

[5]  J. Cazenave,et al.  Prostacyclin (epoprostenol) as the sole antithrombotic agent in postdilutional hemofiltration. , 1988, Nephron.

[6]  S. Jamieson,et al.  Proper donor selection for heart-lung transplantation. The Stanford experience. , 1987, The Journal of thoracic and cardiovascular surgery.

[7]  C. Fisher,et al.  Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374). , 1987, Surgery.

[8]  H. Schäfers,et al.  Prostacyclin as an additive to single crystalloid flush: improved pulmonary preservation in heart-lung transplantation. , 1987, Transplantation proceedings.

[9]  J. Moake,et al.  Alterations in hemostatic parameters during hemodialysis with dialyzers of different membrane composition and flow design. Platelet activation and factor VIII-related von Willebrand factor during hemodialysis. , 1987, The American journal of medicine.

[10]  M. Molzahn,et al.  Effect of Dialyzer Membranes on in Vitro Generation of Eicosanoids , 1987, The International journal of artificial organs.

[11]  P. J. Simpson,et al.  Free radicals and myocardial ischemia and reperfusion injury. , 1987, The Journal of laboratory and clinical medicine.

[12]  P. J. Simpson,et al.  Iloprost Inhibits Neutrophil Function In Vitro and In Vivo and Limits Experimental Infarct Size in Canine Heart , 1987, Circulation research.

[13]  R. S. Mitchell,et al.  A prospective, randomized study of the effects of prostacyclin on neuropsychologic dysfunction after coronary artery operation. , 1987, The Journal of thoracic and cardiovascular surgery.

[14]  A. Harjula,et al.  Lung transplantation in the pig with successful preservation using prostaglandin E-1 , 1987 .

[15]  U. Kucich,et al.  Human neutrophil degranulation during extracorporeal circulation , 1987 .

[16]  C. Fisher,et al.  Quantitation of platelet preservation with prostanoids during simulated bypass. , 1987, The Journal of surgical research.

[17]  P. J. Simpson,et al.  Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. , 1987, American heart journal.

[18]  C. Dollery,et al.  Prostacyclin in the circulation of patients with vascular disorders undergoing surgery. , 1986, Clinical science.

[19]  C. Wildevuur,et al.  Platelet damage by protamine and the protective effect of prostacyclin: an experimental study in dogs. , 1986, The Annals of thoracic surgery.

[20]  L. Evangelisti,et al.  Prostacyclin and heparin during haemodialysis: comparative effects. , 1986, Life support systems : the journal of the European Society for Artificial Organs.

[21]  M. Buckley,et al.  Effect of experimental cardiopulmonary bypass on systemic and transcardiac thromboxane B2 levels. , 1986, The Journal of thoracic and cardiovascular surgery.

[22]  M. Lamy,et al.  Prostaglandin E2, prostacyclin, and thromboxane changes during nonpulsatile cardiopulmonary bypass in humans. , 1986, The Journal of thoracic and cardiovascular surgery.

[23]  K. Rådegran,et al.  Cerebral blood flow and metabolism during cardiopulmonary bypass with special reference to effects of hypotension induced by prostacyclin. , 1986, The Annals of thoracic surgery.

[24]  N. Nicholson,et al.  Evaluation of a stable 5-F prostacyclin analogue as an antithrombotic agent in haemodialysis. , 1986, Drugs under experimental and clinical research.

[25]  C. Kjellstrand,et al.  The effect of prostaglandin inhibition on the clinical course of chronic hemodialysis. , 1986, Nephron.

[26]  R. Venuto,et al.  Hemodynamic consequences of bronchial flow during cardiopulmonary bypass. , 1986, The Journal of thoracic and cardiovascular surgery.

[27]  R. Cotran,et al.  Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion. , 1985, The American journal of pathology.

[28]  K. Rådegran,et al.  Effects of prostacyclin infusion on renal function during cardiopulmonary bypass. , 1985, The Annals of thoracic surgery.

[29]  R. Hakim,et al.  Hemodialysis-associated platelet activation and thrombocytopenia. , 1985, The American journal of medicine.

[30]  R. L. Elliott,et al.  The effects of prostacyclin (PGI2) on haematological and haemodynamic parameters, and lung histology in puppies undergoing cardiopulmonary bypass surgery with profound hypothermia. , 1985, Prostaglandins, leukotrienes, and medicine.

[31]  K. Berg,et al.  Toxicity of plasma from hemodialysis patients treated with heparin or prostacyclin. , 2009, Acta medica Scandinavica.

[32]  L. Cohn,et al.  Disadvantages of prostacyclin infusion during cardiopulmonary bypass: a double-blind study of 50 patients having coronary revascularization. , 1984, The Annals of thoracic surgery.

[33]  C. Blomstrand,et al.  Hypotension induced by prostacyclin treatment during cardiopulmonary bypass does not increase the risk of cerebral complications. , 1984, The Journal of thoracic and cardiovascular surgery.

[34]  E. Ritz,et al.  Plastic filing from dialysis tubing induces prostanoid release from macrophages. , 1984, Kidney international.

[35]  B. Pitt.  Metabolic functions of the lung and systemic vasoregulation. , 1984, Federation proceedings.

[36]  R. Cotran,et al.  Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells , 1984, The Journal of experimental medicine.

[37]  G. Hempelmann,et al.  [Hemodynamics and changes in compliance of the extra-thoracic capacity system following administration of prostacyclin (PGI2)]. , 1984, Herz.

[38]  W. Marasco,et al.  Stimulus specificity of prostaglandin inhibition of rabbit polymorphonuclear leukocyte lysosomal enzyme release and superoxide anion production. , 1984, The American journal of pathology.

[39]  C. Thiemermann,et al.  Inhibition of oxygen-centered free radical formation by the stable prostacyclin-mimetic iloprost (ZK 36 374) in acute myocardial ischemia. , 1984, Journal of cardiovascular pharmacology.

[40]  C. Wildevuur,et al.  Improved functional recovery of the isolated rat heart after 24 hours of hypothermic arrest with a stable prostacyclin analogue (ZK 36 374). , 1983, Journal of molecular and cellular cardiology.

[41]  C. Wildevuur,et al.  The effect of prostaglandin E1 in patients undergoing clinical cardiopulmonary bypass. , 1983, The Annals of thoracic surgery.

[42]  M. Dunn,et al.  Prostacyclin substitution for heparin in long-term hemodialysis. , 1982, The American journal of medicine.

[43]  I. Walker,et al.  Prostacyclin in cardiopulmonary bypass operations. , 1982, The Journal of thoracic and cardiovascular surgery.

[44]  M. Dunn,et al.  Neutrophil adhesiveness during prostacyclin and heparin hemodialysis. , 1982, Blood.

[45]  A. Gimson,et al.  EARLIER CHARCOAL HAEMOPERFUSION IN FULMINANT HEPATIC FAILURE , 1982, The Lancet.

[46]  M. Buckley,et al.  Thromboxane and prostacyclin changes during cardiopulmonary bypass with and without pulsatile flow. , 1982, The Journal of thoracic and cardiovascular surgery.

[47]  J. V. Bannister,et al.  Enhanced production of hydroxyl radicals by the xanthine-xanthine oxidase reaction in the presence of lactoferrin. , 1982, Biochimica et biophysica acta.

[48]  A. Carpentier,et al.  [Clinical study of prostacyclin in extracorporeal circulation. Effects on hemodynamics and coagulation]. , 1982, Archives des maladies du coeur et des vaisseaux.

[49]  Jacob Hs.  The role of activated complement and granulocytes in shock states and myocardial infarction. , 1981 .

[50]  I. Walker,et al.  A Double Blind Study of Prostacyclin in Cardiopulmonary Bypass Surgery , 1981, British journal of haematology.

[51]  H. Sinzinger,et al.  Treatment of chronic kidney transplant rejection with prostacyclin - reduction of platelet deposition in the transplant; prolongation of platelet survival and improvement of transplant function. , 1981, Prostaglandins.

[52]  L. Cohn,et al.  Preservation of Platelets and Their Function in Prolonged Cardiopulmonary Bypass Using Prostacyclin , 1981, Circulation.

[53]  P. Ward,et al.  Suppression of human polymorphonuclear function after intravenous infusion of prostaglandin E1. , 1981, Prostaglandins and medicine.

[54]  O. Ylikorkala,et al.  Increased prostacyclin and thromboxane production in man during cardiopulmonary bypass. , 1981, The Journal of thoracic and cardiovascular surgery.

[55]  R. Hamburger,et al.  A comparison of prostacyclin and heparin on hemodialyses in dogs. , 1981, Prostaglandins.

[56]  C. N. Gillis,et al.  Influence of the lung on arterial levels of endogenous prostaglandins E and F. , 1981, Journal of applied physiology: respiratory, environmental and exercise physiology.

[57]  D. Cocchetto,et al.  Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. , 1981, The New England journal of medicine.

[58]  D. Longmore,et al.  PROSTACYCLIN ADMINISTRATION DURING CARDIOPULMONARY BYPASS IN MAN , 1981, The Lancet.

[59]  S. Hanson,et al.  Prevention of acquired transient defect in platelet plug formation by infused prostacyclin. , 1981, Blood.

[60]  D. Stroncek,et al.  Complement activation and neutropenia occurring during cardiopulmonary bypass. , 1981, The Journal of thoracic and cardiovascular surgery.

[61]  L. Eijsman,et al.  Hemodynamic Side Effects of Prostaglandin E1 in Patients before and during Cardiopulmonary Bypass , 1981, The Thoracic and cardiovascular surgeon.

[62]  M. Sobel,et al.  Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass. , 1981, The Journal of thoracic and cardiovascular surgery.

[63]  H. Sinzinger,et al.  Platelet microaggregates and release of endogenous prostacyclin during the initial phase of haemodialysis. , 1981, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

[64]  R. Colman,et al.  Prostacyclin in lieu of anticoagulation with heparin for extracorporeal circulation. , 1981, Transactions - American Society for Artificial Internal Organs.

[65]  T. Akiba,et al.  Evaluation of prostaglandin D2 (PGD2) as an anticoagulative agent for haemodialysis in comparison with prostaglandin E1 (PGE1). , 1981, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

[66]  D. Longmore.  Experience with prostacyclin in cardiopulmonary bypass in dog and man. , 1981, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[67]  P. Ward,et al.  Suppression by prostaglandin E1 of vascular permeability induced by vasoactive inflammatory mediators. , 1980, Journal of immunology.

[68]  G. Girard,et al.  The action of leukotriene B4 (LTB4) on the lung. , 1980, Prostaglandins and medicine.

[69]  L. McManus,et al.  Complement localization and mediation of ischemic injury in baboon myocardium. , 1980, The Journal of clinical investigation.

[70]  M. Bewick,et al.  EXPERIMENTAL ASSESSMENT OF PROSTACYCLIN IN THE HARVESTING OF KIDNEYS FOR TRANSPLANTATION , 1980, Transplantation.

[71]  J. Turney,et al.  PLATELET PROTECTION AND HEPARIN SPARING WITH PROSTACYCLIN DURING REGULAR DIALYSIS THERAPY , 1980, The Lancet.

[72]  J. Vane,et al.  Prostacyclin eliminates the thrombocytopenia associated with charcoal hemoperfusion and minimizes heparin and fibrinogen consumption. , 1980, Artificial organs.

[73]  J. Copeland,et al.  Platelet loss during experimental cardiopulmonary bypass and its prevention with prostacyclin. , 1980, Annals of Thoracic Surgery.

[74]  I. Cohen.  Platelet structure and function role of prostaglandins. , 1980, Annals of clinical and laboratory science.

[75]  E. Salzman,et al.  Elevated Plasma Fibrinopeptide A ana Thromboxane B2 Levels During Cardiopulmonary Bypass , 1980, Circulation.

[76]  Roger Williams,et al.  PROSTACYCLIN TO PREVENT PLATELET ACTIVATION DURING CHARCOAL HÆMOPERFUSION IN FULMINANT HEPATIC FAILURE , 1980, The Lancet.

[77]  B. Marshall,et al.  Bradykinin, plasma protein fraction, and hypotension. , 1980, The Annals of thoracic surgery.

[78]  W. Zapol,et al.  Plasma thromboxane and prostacyclin metabolites in sheep partial cardiopulmonary bypass. , 1980, Transactions - American Society for Artificial Internal Organs.

[79]  R. L. Elliott,et al.  Effects of Prostaglandin E1, prostacyclin, and tolazoline on elevated pulmonary vascular resistance in neonatal swine. , 1980, Advances in prostaglandin and thromboxane research.

[80]  I. Fong,et al.  The value of prophylactic antibiotics in aorat-coronary bypass operations: a double-blind randomized trial. , 1979 .

[81]  C. J. Lambert,et al.  The Treatment of Postperfusion Bleeding Using ε-Aminocaproic Acid, Cryoprecipitate, Fresh-Frozen Plasma, and Protamine Sulfate , 1979 .

[82]  R. Hughes,et al.  The use of prostacyclin, PGI2, in the prevention of platelet aggregation during charcoal haemoperfusion. , 1979, The International journal of artificial organs.

[83]  R. Egan,et al.  Reduction of hydroperoxides in the prostaglandin biosynthetic pathway by a microsomal peroxidase. , 1979, The Journal of biological chemistry.

[84]  D. Longmore,et al.  PROSTACYCLIN: A SOLUTION TO SOME PROBLEMS OF EXTRACORPOREAL CIRCULATION Experiments in Greyhounds , 1979, The Lancet.

[85]  C. Soriano,et al.  Cardiopulmonary bypass: Associated hemostatic abnormalities , 1979 .

[86]  R. Colman,et al.  Effects of prostaglandin E1 on platelet loss during in vivo and in vitro extracorporeal circulation with a bubble oxygenator. , 1979, The Journal of thoracic and cardiovascular surgery.

[87]  J. Vane,et al.  PROSTACYCLIN CAN REPLACE HEPARIN IN HÆMODIALYSIS IN DOGS , 1978, The Lancet.

[88]  K. Herbaczyńska-Cedro,et al.  Increased blood level of prostaglandin-like substances during cardiopulmonary bypass in the dog. , 1978, Cardiovascular research.

[89]  A. Dalmasso,et al.  Complement activation and pulmonary leukotasis during nylon fiber filtration leukapheresis. , 1978, Blood.

[90]  Gerrard Jm,et al.  Prostaglandins and thromboxanes: "middlemen" modulating platelet function in hemostasis and thrombosis. , 1978 .

[91]  H. Holmsen.  Prostaglandin Endoperoxide – Thromboxane Synthesis and Dense Granule Secretion as Positive Feedback Loops in the Propagation of Platelet Responses during “The Basic Platelet Reaction” , 1977, Thrombosis and Haemostasis.

[92]  A. Dalmasso,et al.  Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. , 1977, The Journal of clinical investigation.

[93]  G. Machiedo,et al.  Prostaglandin influence on pulmonary intravascular leukocytic aggregation during cardiopulmonary bypass. , 1977, The Journal of thoracic and cardiovascular surgery.

[94]  J. Feijen.  Thrombogenesis Caused by Blood-Foreign Surface Interaction , 1977 .

[95]  B. Scharschmidt,et al.  The use of calcium chelating agents and prostaglandin E to eliminate platelet and white blood cell losses resulting from hemoperfusion through uncoated charcoal, albumin-agarose gel, and neutral and cation exchange resins. , 1977, The Journal of laboratory and clinical medicine.

[96]  J. Humphrey,et al.  Letter: International units and standards. , 1976, Lancet.

[97]  F. Bachmann,et al.  The hemostatic mechanism after open-heart surgery. I. Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation. , 1975, The Journal of thoracic and cardiovascular surgery.

[98]  A. Goldman,et al.  Complement-mediated release of histamine from human leukocytes. , 1975, Journal of immunology.

[99]  E. Wilander,et al.  Letter: Diabetogenic nitrosamines? , 1974, Lancet.

[100]  B Chance,et al.  The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. , 1973, The Biochemical journal.

[101]  A. G. Osler,et al.  Lysosomal enzyme release from human leukocytes: mediation by the alternate pathway of complement activation. , 1973, Journal of immunology.